Literature DB >> 17370651

[Peptide vaccination therapy for malignant glioma].

Ryuya Yamanaka1, Kyogo Itoh.   

Abstract

Despite advances in radiation and chemotherapy along with surgical resectioning, the prognosis of patients with malignant glioma is poor. Therefore, the development of a new treatment modality is extremely important. There are increasing reports demonstrating that systemic immunotherapy using peptide is capable of inducing an antiglioma response. This review highlights peptide-based immunotherapy for glioma patients. Peptide-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response and increase survival in patients with glioma. Peptide-based therapy of glioma seems to be safe and without major side effects. Biotherapy for malignant glioma with peptide will open a novel reality now.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17370651

Source DB:  PubMed          Journal:  Brain Nerve        ISSN: 1881-6096


  1 in total

1.  T-cell epitope finding on EPHA2 for further glioma vaccine development: An immunomics study.

Authors:  Viroj Wiwanitkit
Journal:  J Pediatr Neurosci       Date:  2011-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.